关于钆基对比剂在常见成人颅内肿瘤诊断与监测中使用建议的综述
本文综述钆基对比剂(GBCAs)在胶质瘤、脑膜瘤、垂体腺瘤、颅神经肿瘤和转移瘤等常见成人颅内肿瘤影像中的使用建议。高场MRI、3D T2加权序列、动脉自旋标记灌注成像及合成图像等无对比剂技术可在许多良性或稳定病变中替代GBCAs,而GBCAs对某些高级别胶质瘤和复杂肿瘤病例仍不可或缺。
要点
- 高场MRI和3D T2加权序列可减少良性或稳定颅内肿瘤对GBCAs的依赖。
- 动脉自旋标记灌注成像和合成图像可作为无对比剂替代方法。
- GBCAs对某些高级别胶质瘤和复杂肿瘤病例仍属必需。
核心结论
- GBCAs对某些高级别胶质瘤和复杂肿瘤病例仍属必需,但替代影像技术常可在许多良性或稳定病变中替代GBCAs,从而保证诊断准确性并优先考虑患者安全。
研究设计与样本
- 本文为综述,评估GBCAs在胶质瘤、脑膜瘤、垂体腺瘤、颅神经肿瘤和转移瘤等最常见颅内肿瘤影像中的作用。
诊断标准与关键数值
- 高场MRI扫描仪和3D T2加权序列提供优异的软组织对比,为最小化或消除GBCAs使用提供重要机会。
- 动脉自旋标记灌注成像和获得合成图像等先进MRI方法作为无对比剂成像的非侵入性替代方案。
- 超高弛豫率对比剂的发展为需要GBCAs时降低剂量提供了可能。
临床应用与阅片要点
- 在良性或稳定颅内肿瘤病变中,可考虑采用高场MRI、3D T2加权序列、动脉自旋标记灌注成像或合成图像等无对比剂技术以减少或避免GBCAs使用。
- 对某些高级别胶质瘤和复杂肿瘤病例,GBCAs仍属必需。
- 当需要GBCAs时,超高弛豫率对比剂可能有助于降低剂量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gadolinium-based contrast agents (GBCAs) have been indispensable in intracranial tumour imaging, particularly for detecting and characterising malignant lesions, as well as assessing treatment response and disease progression. However, growing concerns about gadolinium deposition in the central nervous system and its environmental impact have prompted a re-evaluation of its use, particularly in the management of benign or stable lesions. This review examines the role of GBCAs in imaging the most common types of intracranial tumours, including gliomas, meningiomas, pituitary adenomas, cranial nerve tumours, and metastases. Recent advancements in high-field MRI scanners and the increasing adoption of 3D T2-weighted sequences, which provide excellent soft-tissue contrast, offer significant opportunities to minimise or eliminate GBCA use. Moreover, advanced MRI methods, such as arterial spin labelling for perfusion imaging and the obtention of synthetic images, have emerged as non-invasive alternatives that further enable contrast-free imaging. Finally, the development of ultra-high-relaxivity contrast agents offers the potential to reduce doses when GBCAs are required. While GBCAs remain essential for imaging certain high-grade gliomas and complex tumour cases, alternative imaging techniques can often replace them in many benign or stable lesions, ensuring diagnostic accuracy and prioritising patient safety. This review highlights strategies to optimise GBCA use, focusing on reducing reliance on GBCAs across different intracranial tumour types. KEY POINTS: Question Current neuro-oncological imaging protocols require refinement to reduce unnecessary gadolinium exposure, mitigate tissue deposition and environmental impact, and maintain diagnostic accuracy. Findings Findings reveal that alternative imaging techniques, including high-field MRI and non-contrast protocols, can reduce GBCAs usage in benign and stable brain tumours. Clinical relevance Minimising gadolinium exposure by reducing or avoiding GBCAs in intracranial tumour imaging effectively mitigates CNS gadolinium retention, lowers environmental impact and toxicity risks, while preserving diagnostic accuracy, enhancing patient safety, and optimising clinical workflows, especially for benign or stable tumours.
引用
- Doniselli FM, Ramos J, Hilario A, et al. Recommendations on the use of gadolinium-based contrast agents in the diagnosis and monitoring of common adult intracranial tumours. Eur Radiol. 2025. PMID: 40478344. doi:10.1007/s00330-025-11646-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。